A Phase 1 interventional study of Denosumab CP4 and Denosumab CP2 in Healthy Volunteer, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-29.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the bioequivalence based on pharmacokinetics (PK) of a single 120 mg subcutaneous dose of denosumab administered to healthy volunteers using denosumab CP4 or denosumab CP2 drug products.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion:
Exclusion Criteria:
Prior diagnosis of bone disease, or any condition that will affect bone metabolism such as, but not limited to: osteoporosis, osteogenesis imperfecta, hyperparathyroidism, hyperthyroidism, hypothyroidism, osteomalacia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, current flare-up of osteoarthritis and/or gout, active , renal disease (defined as [GFR] \< 45 mL/min), Paget's disease of the bone, recent bone fracture (within 6 months), malabsorption syndrome
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
Drug: Denosumab CP4
Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
Drug: Denosumab CP2
Denosumab produced by a process referred to as CP4, administered subcutaneously.
Denosumab produced by a process referred to as CP2, administered subcutaneously.
Also known as: XGEVA®
Maximum Observed Drug Concentration (Cmax) of Denosumab
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
Time frame: Day 1 predose up to day 127
Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
Time frame: Day 1 predose up to day 127
Time to Maximum Observed Concentration (Tmax) of Denosumab
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
Time frame: Day 1 predose up to day 127
Half-life (T1/2) of Denosumab
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
Time frame: Day 1 predose up to day 127
Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis. AUEC0-18 weeks was estimated using the linear-log trapezoidal method.
Time frame: Day 1 predose up to day 127
Maximum Percent Inhibition (Imax) of Serum CTX1
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.
Time frame: Day 1 predose up to day 127
Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.
Time frame: Day 1 predose up to day 127
Number of Participants With Adverse Events
A treatment-related adverse event (TRAE) is any treatment-emergent adverse event (AE) that per investigator review has a reasonable possibility of being caused by the investigational product.
Time frame: From the first dose of denosumab through day 126
Number of Participants Who Developed Anti-denosumab Antibodies
Time frame: Predose on day 1, and days 29, 67 and 127
This study was conducted at 2 centers in the United States.
| Milestone | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Started | 72 | 74 |
| Received treatment | 71 | 71 |
| Completed | 65 | 66 |
| Not completed | 7 | 8 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Decision by sponsor | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 3 |
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
| μg/mL | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Maximum Observed Drug Concentration (Cmax) of Denosumab | 12.7 ± 3.53 | 11.8 ± 3.51 |
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
| day*μg/mL | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab | 579 ± 190 | 555 ± 166 |
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
| days | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Time to Maximum Observed Concentration (Tmax) of Denosumab | 6.9 (2.0 to 14) | 7.0 (3.0 to 21) |
Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.
| days | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Half-life (T1/2) of Denosumab | 23.9 ± 10.1 | 22.4 ± 10.2 |
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis. AUEC0-18 weeks was estimated using the linear-log trapezoidal method.
| day*percent inhibition | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks) | 8380 ± 2050 | 8190 ± 2250 |
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.
| percent inhibition | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Maximum Percent Inhibition (Imax) of Serum CTX1 | 69.8 ± 17.0 | 70.3 ± 13.7 |
Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.
| days | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1 | 3.01 (0.0 to 112) | 3.96 (1.0 to 126) |
A treatment-related adverse event (TRAE) is any treatment-emergent adverse event (AE) that per investigator review has a reasonable possibility of being caused by the investigational product.
| participants | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Any adverse event | 26 | 24 |
| Serious adverse events | 0 | 1 |
| AEs leading to discontinuation of denosumab | 0 | 0 |
| Fatal adverse events | 0 | 0 |
| Treatment-related adverse events (TRAEs) | 4 | 6 |
| Treatment-related serious adverse events | 0 | 0 |
| TRAEs leading to discontinuation of denosumab | 0 | 0 |
| Treatment-related fatal adverse events | 0 | 0 |
| participants | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Number of Participants Who Developed Anti-denosumab Antibodies | 0 | 0 |
Collected over From the first dose of denosumab through day 126. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab CP4 | — | 0/71 (0%) | 26/71 (36.6%) |
| Denosumab CP2 | — | 1/71 (1.4%) | 24/71 (33.8%) |
| Event | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| Abscess limbInfections and infestations | 0/71 | 1/71 |
| Event | Denosumab CP4 | Denosumab CP2 |
|---|---|---|
| HeadacheNervous system disorders | 6/71 | 4/71 |
| NauseaGastrointestinal disorders | 3/71 | 0/71 |
| Upper respiratory tract infectionInfections and infestations | 2/71 | 2/71 |
| ExcoriationInjury, poisoning and procedural complications | 0/71 | 2/71 |
| Blood calcium decreasedInvestigations | 2/71 | 2/71 |
| Blood phosphorus decreasedInvestigations | 1/71 | 2/71 |
| Back painMusculoskeletal and connective tissue disorders | 1/71 | 2/71 |
| GoitreEndocrine disorders | 0/71 | 1/71 |
| Eye pruritusEye disorders | 1/71 | 0/71 |
| Scleral discolourationEye disorders | 1/71 | 0/71 |
The Safety Analysis Set defined as all participants who were enrolled and received denosumab.
| Age, Continuous(years) | Denosumab CP4 | Denosumab CP2 | Total |
|---|---|---|---|
| Mean | 38.9 ± 10.9 | 37.6 ± 11.3 | 38.3 ± 11.1 |
| Sex: Female, Male(Participants) | Denosumab CP4 | Denosumab CP2 | Total |
|---|---|---|---|
| Female | 29 | 33 | 62 |
| Male | 42 | 38 | 80 |
| Race/Ethnicity, Customized(participants) | Denosumab CP4 | Denosumab CP2 | Total |
|---|---|---|---|
| Asian | 5 | 4 | 9 |
| Black (or African American) | 24 | 24 | 48 |
| Multiple | 3 | 1 | 4 |
| White | 39 | 42 | 81 |
| Race/Ethnicity, Customized(participants) | Denosumab CP4 | Denosumab CP2 | Total |
|---|---|---|---|
| Hispanic/Latino | 20 | 23 | 43 |
| Not Hispanic/Latino | 51 | 48 | 99 |
The record gives a start of Feb 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab